With the increasing aging of the population and the increase in the use of electronic products, age-related eye diseases, metabolism-related eye diseases, and fundus lesions caused by high myopia are increasing
.
In this regard, since the release of the "13th Five-Year" National Eye Health Plan (2016-2020) in 2016, eye health has been put on the national strategic height
.
Some institutions predict that from 2020 to 2024, the compound annual growth rate of China's ophthalmic medical service market will be 11.
05%, and the market size will reach 223.
1 billion yuan
by 2024.
The market prospect in the field of ophthalmic medicine is broad, and its research and development field is attracting the participation
of many pharmaceutical companies.
In April this year, Jixing Pharmaceutical announced the introduction of two research presbyopia therapeutics drugs developed by the American company LENZ Therapeutics in China with an advance payment of $110 million and a potential milestone payment
.
It is reported that the company has also reached cooperation with the American company Oyster Point Pharma and the Portuguese company Hovione in the past two years to lay out the field of
presbyopia and dry eye treatment drugs.
Hebo Pharmaceutical introduced the "global new" drug tenazeptin (HBM9036) eye drops from the Korean company HanAll Biopharma for the treatment of moderate to severe dry eye, and it has completed phase III clinical trials of the drug
.
The industry said that in recent years, with the rise of ophthalmic drug companies in China, domestic enterprises have gradually occupied an important position, of which Kanghong Pharmaceutical and Xingqi Eye Medicine are representatives
.
Taking Xingqi Eye Medicine as an example, the data shows that the company has established a "full series and many varieties" ophthalmic drug product system
.
The company's products include ophthalmic anti-infectives, ophthalmic anti-inflammatory/anti-infectives, mydriatic drugs and ciliary muscle paralysis drugs, ophthalmic non-steroidal anti-inflammatory drugs, mydriatic drugs and anti-glaucoma drugs, covering ten sub-categories of ophthalmic drugs, can produce gels, eye drops, eye ointments and other dosage forms, providing high-quality products
for the treatment of ophthalmic diseases.
Data show that in the first half of 2022, Xingqi Eye Drugs achieved a year-on-year increase in revenue of 29.
89%.
It is reported that Xingqi Eye Drugs has continuously increased R&D investment in recent years to better develop drugs
that meet market demand.
The data shows that in the past 5 years, the proportion of Xingqi eye drug research and development investment in operating income has increased year by year, of which its research and development investment accounted for 11.
02% of the company's operating income in 2021, and in the first half of this year, its research and development investment increased by 67% year-on-year, reaching more than 82.
1 million yuan
.
Analysts said that the visual impairment and complications caused by ophthalmic diseases will affect the quality of life of patients, whether it is the myopia problem of adolescents, the dry eye problems caused by excessive use of eyes by students and office workers, or the eye health needs of the elderly, all of which require professional eye treatment, which will bring great opportunities
for the ophthalmic drug industry.
At the same time, with the gradual popularization of eye health knowledge among Chinese residents, people's awareness of eye health care is increasing, and the demand for ophthalmic drugs will continue to grow
.
The industry predicts that the domestic ophthalmic drug market will grow from about 26 billion yuan to 100 billion yuan in
the next decade.
In addition, data predict that by 2024, the size of China's ophthalmic medical service market will reach 223.
1 billion yuan.
In the face of a huge market, the capital market certainly does not miss the opportunity to dig gold
.
According to the statistics of institutions, since 2021, a total of 8 investment and financing transactions
have been completed in the field of domestic ophthalmic treatment.
In recent years, many investment institutions, including Sequoia China, Hillhouse Investment, Gao Tejia, Zhengxingu Capital, etc.
, have participated in the layout
of the ophthalmic treatment field.
The industry said that ophthalmology, as the golden track that the capital market focuses on betting, is mainly reflected in two aspects, one is in the medical service side, Huaxia Ophthalmology, Puri Ophthalmology, Xima Ophthalmology and other intensive listings; Second, on the product side, ophthalmic innovative pharmaceutical companies have become the darlings
of the capital market.
However, some analysts said that as the State Food and Drug Administration has broadened the green channel for drug review, the approval of ophthalmic drug registration approvals has accelerated, and market competition has become more and more intense
.
